Could a daily ketone drink help older adults think sharper and age healthier?

NCT ID NCT06068803

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study investigates whether drinking a ketone supplement three times a day for four weeks can improve blood sugar control, reduce inflammation, and enhance cognitive function in adults aged 60 to 80. Participants are randomly assigned to receive either the ketone drink or a taste-matched placebo, and their health is tracked through blood tests, fat tissue samples, cognitive tasks, and wearable monitors. The goal is to see if this simple supplement can support healthier aging.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a ketone monoester drink called D-β-hydroxybutyrate-R 1,3-Butanediol
What this could lead to
If it works, this could point toward a simple dietary supplement that helps older adults maintain better blood sugar control, reduce inflammation, and support brain function.
What could go wrong
This is a small, early-stage trial with only 32 participants, so results may not apply to everyone. The supplement may cause digestive discomfort or have no measurable benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

32 people

The number who actually took part.

Started

Sep 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 60 to 80 years * Postmenopausal women must be \>1 year since last menses * Able to provide informed consent * Willing and able to comply with all study procedures including randomisation into any of the experimental groups; maintenance of habitual dietary intake, exercise, medication and supplement use over the 28-day intervention period; blood draws and adipose tissue biopsies; and abstinence from alcohol (\>24 h), food (\>10 h) and strenuous exercise (\>3 d) prior to trial days. Exclusion Criteria: * Living in a residential care home * Unstable or clinically active pulmonary, cardiac, hepatic, renal, endocrine, hematologic, immunologic, neurologic, psychiatric or biliary disorders. 'Unstable' refers to complications of a condition that are not controlled by medication or lifestyle and which require frequent monitoring and testing by a health professional. Stable chronic disease is not an exclusion criterion unless specified. * Diagnosed Type 1 or Type 2 Diabetes Mellitus * Diagnosed gastrointestinal condition which would potentially impact ability to consume study drink (e.g. inflammatory bowel disease, history of gastrointestinal ulcers or bleeding) * Diagnosed autoimmune condition * Previous major cardiovascular event (e.g. heart attack, stroke) * Past or current cancer diagnosis and treatment excluding non-melanoma skin cancers * Severe hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥120 mmHg), as defined by blood pressure measured at Visit 1 * Current tobacco or recreational drug use * Reported changes to use of thyroid, antihypertensive, antidepressant or statin medications within 30 days of Visit 1 * Taking medications that will interfere with the study outcomes * Known negative reaction to lidocaine anaesthetic and/or taking warfarin * Currently following a ketogenic diet or taking ketone supplements * Not weight stable in the prior 3 months (\>5% weight change) * Unable to converse in English

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ketosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Bath

    Bath, Somerset, BA2 7AY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.